Abstract
N/A
Highlights
National guidelines and consensus documents on onychomycosis diagnosis and treatment were last published more than 5 years ago in 2014 (British7) and 2015 (Canadian1)—around the time that both topical efinaconazole and tavaborole were first approved in the US in 2014
Since more clinical data, post hoc analyses, meta-analyses, and FDA-approved indications have become available for onychomycosis drugs
Careful assessment and testing must be performed when diagnosing onychomycosis; nail dystrophy can be induced by other disorders, and many common conditions that can mimic onychomycosis should be ruled out (Figure 1)
Summary
National guidelines and consensus documents on onychomycosis diagnosis and treatment were last published more than 5 years ago in 2014 (British7) and 2015 (Canadian1)—around the time that both topical efinaconazole and tavaborole were first approved in the US in 2014. To provide recommendations for the diagnosis and therapeutic treatment of toenail onychomycosis following a roundtable discussion with the authors on March 15, 2021 Patients aged ≥65 years,diabetic, peripheral vascular disease, or immunocompromised topical treatmentb
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
